Ucwaningo lwe-AMP lwabonisa ukuthi i-monoclonal antibody ye-VRC01 ethena amandla kabanzi ingakuvimbela ngokuphepha ukungenwa yizinhlobo ezithile ze-HIV.

• Kodwa-ke, amadriphu e-VRC01 ye-AMP awazange anikeze indlela enqala yokuvinjelwa kwegciwane le-HIV sekukonke.
• Lokhu kusho ukuthi cishe kuzodingeka sisebenzise ngaphezu kwe-antibody eyodwa ukuze sifinyelele indlela ephumelelayo yokuvimbela i-HIV ngama-antibody.

Ucwaningo lwe-AMP lwabhalisa lwagcwala ngo-Okthoba ka-2018. Izivivinyo ezimbili zokwelashwa zeSigaba 2b ezaqhutshwa yi-HIV Vaccine Trials Network (HVTN) ne-HIV Prevention Trials Network (HPTN) zabhalisa ababambiqhaza abangu-4,625 abasengcupheni yokungenwa yi-HIV abavela emiphakathini yaseNyakatho naseNingizimu Melika, eYurophu, nase-Afrika eseningizimu yeSahara.

Lolu cwaningo luyaqhubeka futhi lusafihliwe kuze kube yilapho bonke ababambiqhaza sebeqede ukuvakasha kwabo kocwaningo kokugcina, okulindeleke ukuthi kube sekuqaleni kuka-2021.

Ulwazi oluthe xaxa mayelana noCwaningo lwe-AMP nemiphumela lungatholakala lapha:

• Imibuzo Ephakama Njalo Ngemiphumela YoCwaningo lwe-AMP
• Umbiko Wemiphumela Womphakathi